HK1052874B - Compositions containing a naphthalmide and an antiproliferative agent - Google Patents
Compositions containing a naphthalmide and an antiproliferative agentInfo
- Publication number
- HK1052874B HK1052874B HK03105124.5A HK03105124A HK1052874B HK 1052874 B HK1052874 B HK 1052874B HK 03105124 A HK03105124 A HK 03105124A HK 1052874 B HK1052874 B HK 1052874B
- Authority
- HK
- Hong Kong
- Prior art keywords
- agents
- naphthalimide
- antiproliferative agent
- antiproliferative
- host
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a naphthalimide and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the naphthalimide comprises amonafide (5-amino-2-[2-(dimethylamine)ethyl]-1H-benz[de-]isoquinoline-1,3-(2H)-dione). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes. The invention comprises the described methods as well as compositions comprising a naphthalimide and an antiproliferative agent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19710300P | 2000-04-12 | 2000-04-12 | |
PCT/US2001/012169 WO2001078705A2 (en) | 2000-04-12 | 2001-04-12 | Compositions containing a naphthalmide and an antiproliferative agent |
Publications (2)
Publication Number | Publication Date |
---|---|
HK1052874A1 HK1052874A1 (en) | 2003-10-03 |
HK1052874B true HK1052874B (en) | 2006-05-04 |
Family
ID=22728064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03105124.5A HK1052874B (en) | 2000-04-12 | 2003-07-15 | Compositions containing a naphthalmide and an antiproliferative agent |
Country Status (10)
Country | Link |
---|---|
US (2) | US6630173B2 (en) |
EP (1) | EP1274458B1 (en) |
JP (1) | JP2003530431A (en) |
AT (1) | ATE305312T1 (en) |
AU (1) | AU5348301A (en) |
CA (1) | CA2404278C (en) |
DE (1) | DE60113666T2 (en) |
ES (1) | ES2248312T3 (en) |
HK (1) | HK1052874B (en) |
WO (1) | WO2001078705A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1263440B1 (en) * | 2000-03-15 | 2006-06-21 | ChemGenex Pharmaceuticals, Inc. | Cephalotaxine alkaloid combination compositions and uses thereof |
JP2003530431A (en) * | 2000-04-12 | 2003-10-14 | ケムジェネックス・セラピューティクス・インコーポレイテッド | Composition containing naphthalimide and antiproliferative agent |
US20060211648A1 (en) * | 2000-04-12 | 2006-09-21 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
US7135481B2 (en) * | 2000-04-12 | 2006-11-14 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
US20050170015A1 (en) * | 2000-10-31 | 2005-08-04 | Brown Dennis M. | Antiproliferative colchicine compositions and uses thereof |
US20050239816A1 (en) * | 2002-04-22 | 2005-10-27 | Xanthus Life Sciences, Inc. | Amonafide salts |
US6693198B2 (en) | 2002-04-22 | 2004-02-17 | Xanthus Life Sciences, Inc. | Amonafide salts |
EP1496880A4 (en) * | 2002-04-24 | 2007-12-12 | Res Dev Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
EP1539150A4 (en) * | 2002-07-08 | 2006-10-11 | Chemgenex Pharmaceuticals Inc | Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof |
AU2003253872A1 (en) * | 2002-07-17 | 2004-02-09 | Chemgenex Pharmaceuticals, Inc. | Formulations and methods of administration of cephalotaxines, including homoharringtonine |
WO2004009030A2 (en) * | 2002-07-22 | 2004-01-29 | Chemgenex Pharmaceuticals Limited | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
CA2554775A1 (en) * | 2004-01-30 | 2005-08-18 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide dosing by n-acetyl transferase genotyping |
US20050288310A1 (en) * | 2004-06-04 | 2005-12-29 | Chemgenex Pharmaceuticals, Inc. | Methods of treating cellular proliferative disease using naphthalimide and PARP-1 inhibitors |
JP2008529667A (en) * | 2005-02-10 | 2008-08-07 | ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド | Medical device |
CA2684219C (en) * | 2007-04-13 | 2017-05-23 | Chemgenex Pharmaceuticals, Inc. | Oral cephalotaxine dosage forms |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183821A (en) * | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
US5420137A (en) * | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
FR2673944B1 (en) * | 1991-03-13 | 1995-03-10 | Sanofi Elf | DERIVATIVES OF 1,8-NAPHTALIMIDE, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
KR20010020611A (en) * | 1997-07-01 | 2001-03-15 | 아테로제닉스, 인코포레이티드 | Antioxidant enhancement of therapy for hyperproliferative conditions |
EP1263440B1 (en) | 2000-03-15 | 2006-06-21 | ChemGenex Pharmaceuticals, Inc. | Cephalotaxine alkaloid combination compositions and uses thereof |
JP2003531138A (en) * | 2000-03-21 | 2003-10-21 | アセロジエニクス・インコーポレイテツド | N-substituted dithiocarbamates for the treatment of biological diseases |
JP2003530431A (en) * | 2000-04-12 | 2003-10-14 | ケムジェネックス・セラピューティクス・インコーポレイテッド | Composition containing naphthalimide and antiproliferative agent |
-
2001
- 2001-04-12 JP JP2001576006A patent/JP2003530431A/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012169 patent/WO2001078705A2/en active IP Right Grant
- 2001-04-12 DE DE60113666T patent/DE60113666T2/en not_active Expired - Lifetime
- 2001-04-12 AT AT01926985T patent/ATE305312T1/en not_active IP Right Cessation
- 2001-04-12 ES ES01926985T patent/ES2248312T3/en not_active Expired - Lifetime
- 2001-04-12 US US09/834,177 patent/US6630173B2/en not_active Expired - Fee Related
- 2001-04-12 CA CA2404278A patent/CA2404278C/en not_active Expired - Fee Related
- 2001-04-12 AU AU5348301A patent/AU5348301A/en not_active Withdrawn
- 2001-04-12 EP EP01926985A patent/EP1274458B1/en not_active Expired - Lifetime
-
2003
- 2003-07-15 HK HK03105124.5A patent/HK1052874B/en not_active IP Right Cessation
- 2003-07-31 US US10/631,106 patent/US20040047918A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2248312T3 (en) | 2006-03-16 |
EP1274458A2 (en) | 2003-01-15 |
ATE305312T1 (en) | 2005-10-15 |
WO2001078705A3 (en) | 2002-06-20 |
AU5348301A (en) | 2001-10-30 |
WO2001078705A2 (en) | 2001-10-25 |
CA2404278C (en) | 2010-03-23 |
EP1274458B1 (en) | 2005-09-28 |
US6630173B2 (en) | 2003-10-07 |
US20020025916A1 (en) | 2002-02-28 |
DE60113666D1 (en) | 2005-11-03 |
DE60113666T2 (en) | 2006-06-14 |
US20040047918A1 (en) | 2004-03-11 |
HK1052874A1 (en) | 2003-10-03 |
JP2003530431A (en) | 2003-10-14 |
CA2404278A1 (en) | 2001-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1052874A1 (en) | Compositions containing a naphthalmide and an antiproliferative agent | |
AU7878301A (en) | Method of amplifying nucleic acid | |
AU4580301A (en) | Cephalotaxine alkaloid compositions and uses thereof | |
AU2001244677A1 (en) | Method of amplifying nucleic acid by using double-stranded nucleic acid as template | |
ATE425165T1 (en) | METHOD FOR PREPARING NUCLEOSIDE METABOLISM INHIBITORS | |
EP1537227A4 (en) | Method for efficient rna interference in mammalian cells | |
HUP0302332A3 (en) | Gene detection method for improving the likelihood of an effective response to an erbb antagoist cancer therapy | |
AP2001002319A0 (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors. | |
AU2001278783A1 (en) | Method of amplifying nucleic acid | |
HK1068375A1 (en) | Method of determining dihydropyrimidine dehydrogenase gene expression | |
WO2001004357A3 (en) | Generic sbe-fret protocol | |
PT1075477E (en) | NEW BENZONEFTIRIDINE N-OXIDES | |
FR2792938B1 (en) | NEWS 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES PHOSPHODIESTERASE IV INHIBITORS | |
WO2001091741A3 (en) | Compositions containing hexitol and an antiproliferative agent | |
WO2000061594A3 (en) | Nucleoside derivatives with photo-unstable protective groups | |
HK1040769A1 (en) | Method for detection and quantification of specific nucleic acid. | |
EP1432725A4 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
AU2003213057A8 (en) | Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid | |
WO2007095639A3 (en) | Napht alimide compositions and uses thereof | |
WO2001091740A3 (en) | Compositions containing naphthaquinone and an antiproliferative agent | |
IL147281A0 (en) | Methods of treating fungal infections with inhibitors of nad synthetase enzyme | |
HUP0300183A3 (en) | Substituted purine derivatives as inhibitors of cell adhesion | |
HUP0303953A3 (en) | Method for preparation of pharmaceutical composition for treating tumors by using tegafur, uracil, folinic acid, and cyclophospamide | |
EP1499628A4 (en) | Rna interference mediated inhibition of stearoyl-coa desaturase (scd) gene expression using short interfering nucleic acid (sina) | |
WO2001080842A3 (en) | Compositions comprising a methylnogarol in combination with an antiproliferative agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20120412 |